文献速递产科麻醉区域麻醉与超声术前评估与围术期医学

妊娠期血管性血友病的麻醉管理:大型病例系列回顾性分析

Anesthetic Management of Von Willebrand Disease in Pregnancy: A Retrospective Analysis of a Large Case Series.
PubMed 文献 · Anesth Analg · 2021-01-01

该回顾性分析描述了单中心2000至2019年间71例血管性血友病(vWD)孕妇共106次分娩的麻醉管理。88.7%的分娩采用了椎管内麻醉,其中28.7%在椎管内麻醉前接受了去氨加压素或vWF/FVIII浓缩物治疗,未观察到麻醉相关不良结局(0/106,0%[95%CI 0-3.4]),产后出血发生11例(10.4%)。

要点

  • vWD孕妇多数可安全接受椎管内麻醉,本系列未发生椎管内血肿或血栓栓塞事件。
  • 椎管内麻醉前是否预处理取决于vWD类型和严重程度,本系列中28.7%的椎管内麻醉前接受了去氨加压素或vWF/FVIII浓缩物。
  • 多学科协作规划对优化vWD患者凝血状态和镇痛麻醉选择至关重要。

核心结论

  • 在本大型病例系列中,大多数vWD孕妇在分娩时接受了椎管内麻醉,未观察到不良事件,提示在所描述的围产期管理下椎管内麻醉可安全实施。

研究设计与样本

  • 回顾性分析,研究对象来自高危产科麻醉会诊服务和机构研究数据库登记诊断代码,手工审查2000年1月1日至2019年1月1日在本院分娩的vWD孕妇记录。

主要发现

  • 106次分娩中94次(88.7%)使用了椎管内麻醉技术。
  • 94次椎管内麻醉中27次(28.7%)在麻醉前接受了去氨加压素或vWF/FVIII浓缩物治疗。
  • 11次分娩(10.4%)发生产后出血(估计失血量≥1000 mL)。
  • 未观察到麻醉相关不良结局(0/106;0%[95%CI 0-3.4]),包括椎管内血肿或血栓栓塞事件。

关键数值与推荐

  • 产后出血定义为估计失血量≥1000 mL,本系列发生率为10.4%(11/106)。
  • 椎管内麻醉前预处理(去氨加压素或vWF/FVIII浓缩物)的使用由vWD类型和严重程度决定,在本系列94次椎管内麻醉中占28.7%(27/94)。

临床怎么用

  • vWD孕妇的麻醉管理应基于多学科共识和患者疾病及产科具体情况个体化决定。
  • 椎管内麻醉前应根据vWD类型和严重程度考虑是否给予去氨加压素或vWF/FVIII浓缩物预处理。
  • 多学科规划有助于优化vWD患者凝血状态并促进镇痛和麻醉方式的选择。

局限性

  • 本研究为单中心回顾性分析,麻醉管理由个体医生酌情决定,可能存在选择偏倚。
  • 样本量有限(71例患者、106次分娩),且部分患者vWD类型未知。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although Von Willebrand disease (vWD) is the most common heritable bleeding disorder, there are limited reports regarding the safety of neuraxial anesthesia in the obstetric population and no definitive guidelines specifying recommended pretreatment or therapies for patients with vWD. The aim of this study is to describe the anesthetic management of pregnant patients with vWD at a large tertiary-care center. METHODS: In this retrospective analysis, the study population was identified from vWD patients evaluated by our high-risk obstetric anesthesia consultation service and by diagnosis codes from our institutional research database registry. We manually reviewed records of patients with vWD in pregnancy who delivered at our institution between January 1, 2000 and January 1, 2019 for demographic characteristics, circumstances of vWD diagnosis, history of bleeding, laboratory studies, and overall management of vWD. Anesthetic management of vWD was at the discretion of individual providers, based on multidisciplinary consensus and the specific circumstances of each patient's disease and obstetric presentation. RESULTS: We identified 106 deliveries among 71 individual vWD patients. Of the unique patients, 54 had vWD type 1, 6 had vWD type 2, and 11 had vWD type unknown. Forty-three cases (40.6%) were cesarean deliveries. Neuraxial techniques were used in 94 of 106 deliveries (88.7%). Treatment with desmopressin or Von Willebrand factor/factor VIII concentrate before neuraxial anesthesia occurred in 27 of 94 neuraxial anesthetics (28.7%). Eleven deliveries (10.4%) were complicated by postpartum hemorrhage (PPH), defined as estimated blood loss of ≥1000 mL. There were no noted adverse anesthetic outcomes (0 of 106; 0% [95% confidence interval, 0-3.4]), including neuraxial hematoma or thromboembolic events. CONCLUSIONS: In this large case series, the majority of vWD patients received neuraxial anesthesia for labor and delivery, with no noted adverse events. This suggests that neuraxial anesthesia can be safely performed with the peripartum management that we describe. Pretreatment was dictated by the type and severity of vWD. Multidisciplinary planning is important to optimize the coagulation status of patients with vWD and facilitate options for analgesia and anesthesia.

来源:Anesth Analg,查看原文。版权归原作者所有。

引用

  1. Reale SC, Farber MK, Lumbreras-Marquez MI, et al. Anesthetic Management of Von Willebrand Disease in Pregnancy: A Retrospective Analysis of a Large Case Series. Anesth Analg. 2021. PMID: 33913917. doi:10.1213/ANE.0000000000005502

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。